Ann: AGM Presentation, page-4

I’m questioning this announcement as price sensitive.

Is it the millions of options given to Board and Management that makes an AGM presentation price sensitive?

Are they beating a dead horse by continuing in the UK?

I doubt any of the previous opportunities (Day Lewis, health programs) earned anything other than a nominal fee to trial and nothing has turned into a contract.

The zero dollars from this market is hidden in the ROW figures.

Looks like it will be a sleepy 2 months … unless they’re trying to shore up December to then make a statement about H1FY23 revenues.